Loading
A phase 2 trial of Abiraterone acetate, Apalutamide, Enzalutamide in metastatic cancer and prostate cancer, run by Sun Pharmaceutical Industries Limited, now recruiting.
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. is a phase 2 interventional study registered as NCT05422911 by Sun Pharmaceutical Industries Limited, with 192 participants planned, started 2022-08-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: Abiraterone acetate, Apalutamide, Enzalutamide. Conditions listed: Metastatic Cancer, Neoplasm, Prostate, Castrate-sensitive, Castrate-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
Shares Apalutamide, Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Apalutamide, Abiraterone acetate, Prostate cancer.